TY - JOUR
KW - Adult
KW - Buprenorphine/supply & distribution/therapeutic use
KW - Drug Utilization
KW - Female
KW - Health Care Surveys
KW - HIV Infections/complications
KW - Humans
KW - Male
KW - Narcotic Antagonists/supply & distribution/therapeutic use
KW - Opioid-Related Disorders/epidemiology/rehabilitation
KW - Physicians
KW - prescriptions
KW - Socioeconomic Factors
KW - Specialization
AU - J. Netherland
AU - M. Botsko
AU - J. E. Egan
AU - A. J. Saxon
AU - C. O. Cunningham
AU - R. Finkelstein
AU - M. N. Gourevitch
AU - J. A. Renner
AU - N. Sohler
AU - L. E. Sullivan
AU - L. Weiss
AU - D. A. Fiellin
AU - BHIVES Collaborative
A1 - 
AB - Buprenorphine is an effective long-term opioid agonist treatment. As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices. Although many patients have benefited from the availability of buprenorphine in the United States, almost half of current prescribers are addiction specialists suggesting that buprenorphine treatment has not yet fully penetrated general practice settings. We examined factors affecting willingness to offer buprenorphine treatment among physicians with different levels of prescribing experience. Based on their prescribing practices, physicians were classified as experienced, novice, or as a nonprescriber and asked to assess the extent to which a list of factors impacted their prescription of buprenorphine. Several factors affected willingness to prescribe buprenorphine for all physicians: staff training; access to counseling and alternate treatment; visit time; buprenorphine availability; and pain medications concerns. Compared with other physicians, experienced prescribers were less concerned about induction logistics and access to expert consultation, clinical guidelines, and mental health services. They were more concerned with reimbursement. These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine.
BT - Journal of substance abuse treatment
C5 - Opioids & Substance Use; Education & Workforce
CP - 3
CY - United States
DO - 10.1016/j.jsat.2008.06.006
IS - 3
JF - Journal of substance abuse treatment
N2 - Buprenorphine is an effective long-term opioid agonist treatment. As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices. Although many patients have benefited from the availability of buprenorphine in the United States, almost half of current prescribers are addiction specialists suggesting that buprenorphine treatment has not yet fully penetrated general practice settings. We examined factors affecting willingness to offer buprenorphine treatment among physicians with different levels of prescribing experience. Based on their prescribing practices, physicians were classified as experienced, novice, or as a nonprescriber and asked to assess the extent to which a list of factors impacted their prescription of buprenorphine. Several factors affected willingness to prescribe buprenorphine for all physicians: staff training; access to counseling and alternate treatment; visit time; buprenorphine availability; and pain medications concerns. Compared with other physicians, experienced prescribers were less concerned about induction logistics and access to expert consultation, clinical guidelines, and mental health services. They were more concerned with reimbursement. These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine.
PP - United States
PY - 2009
SN - 1873-6483; 0740-5472
SP - 244
EP - 251
EP - 
T1 - Factors affecting willingness to provide buprenorphine treatment
T2 - Journal of substance abuse treatment
TI - Factors affecting willingness to provide buprenorphine treatment
U1 - Opioids & Substance Use; Education & Workforce
U2 - 18715741
U3 - 10.1016/j.jsat.2008.06.006
VL - 36
VO - 1873-6483; 0740-5472
Y1 - 2009
ER -